stockrow
Saturday 7 November 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
Benitec Biopharma Limited’s revenue for fiscal 2023 (year ended June 2023) was $75,000.00, up 2.74% from fiscal 2022.
- EPS
- −11.3%
- Free cash flow
- +38.9%
- Total debt
- −46.3%
Quarter to June 2026, against a year earlier
9.50
0.86
+9.95%
Follow BNTC
Alert me
Benitec Biopharma Limited (BNTC) P/E ratio
Benitec Biopharma Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 51.3× (April 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
Low 0.0×
High 51.3×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNTC Benitec Biopharma Limited | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| EIKN Eikon Therapeutics, Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ALEC Alector, Inc. compare | 6.6× |
| AGEN Agenus Inc. compare | 10.7× |
| SCTX Scribe Therapeutics Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)